Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK)

Gert Jan Ossenkoppele, Georg Stussi, Johan Maertens, Kees van Montfort, Bart J. Biemond, Dimitri Breems, August Ferrant, Carlos Graux, Georgine E. de Greef, C. J. M. Halkes, Mels Hoogendoorn, Rene M. Hollestein, Mojca Jongen-Lavrencic, Mark-David Levin, Arjan A. van de Loosdrecht, Marinus van Marwijk Kooij, Yvette van Norden, Thomas Pabst, Harry C. Schouten, Edo VellengaGregor E. G. Verhoef, Okke de Weerdt, Pierre Wijermans, Jakob R. Passweg, Bob Lowenberg

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)4706-4711
JournalBlood
Volume120
Issue number24
DOIs
Publication statusPublished - 6 Dec 2012

Cite this

Ossenkoppele, G. J., Stussi, G., Maertens, J., van Montfort, K., Biemond, B. J., Breems, D., Ferrant, A., Graux, C., de Greef, G. E., Halkes, C. J. M., Hoogendoorn, M., Hollestein, R. M., Jongen-Lavrencic, M., Levin, M-D., van de Loosdrecht, A. A., Kooij, M. V. M., van Norden, Y., Pabst, T., Schouten, H. C., ... Lowenberg, B. (2012). Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood, 120(24), 4706-4711. https://doi.org/10.1182/blood-2012-04-420596